Disclaimer

THIS INFORMATION IS CONFIDENTIAL AND IT IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE COPIED, REPRODUCED, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. THIS PRESENTATION IS NOT FOR DISTRIBUTION IN THE UNITED STATES, THE REPUBLIC OF SOUTH AFRICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

These presentation slides (the "Slides"), the information communicated during any delivery of the Slides (howsoever delivered), including but not limited to any information communicated in any question and answer session and any document or material distributed at or in connection with the Slides (together the "Information") has been prepared by Yourgene Health plc (the "Company", and such term shall also be deemed to include any subsidiaries of the Company) for the sole use at a presentation (the "Presentation") relating to the annual results of the Company for the year ended 31 March 2019. The Information is provided on a confidential basis and is personal to the recipient. The Information does not contain or constitute or form part of an admission document or prospectus nor does the Information contain, constitute, or form part of any offer or invitation to purchase or subscribe for any securities of the Company, or contain or constitute or form part of any solicitation of any offer to purchase or subscribe for any securities of the Company. The Information should not be relied on in connection or a decision to purchase or subscribe for any securities or act as any inducement to enter into any contract or investment decision in relation thereto. The Information does not constitute a recommendation regarding any decision to sell or purchase securities in the Company. Accordingly, the Information is being supplied to you solely for your information only. If you are considering engaging in any investment activity, you should seek appropriate independent advice and make your own assessment. The communication of the Information to you should not be taken as any form of commitment on the part of the Company to proceed with any transaction and the Company reserves its right to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company, Cairn or their respective Affiliates be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. The Information is strictly private and confidential and contains material non-public information. The Information may not, without the consent of Cairn and the Company, be reproduced, disseminated, distributed or otherwise disclosed to any other person or published, in whole or in part, for any purpose. No reliance may be placed, for any purpose whatsoever, on the Information or the completeness or accuracy of the Information. No responsibility is accepted, and to the fullest extent permitted by law or regulation, no representation, warranty or other assurance is made or given, in either case, expressly or impliedly, by or on behalf of the Company, Stifel, or their respective Affiliates or any person as to the accuracy, completeness, fairness or reasonableness of the Information or any opinions contained therein. Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the Information or in connection with it or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them. No duty of care is owed or will be deemed to be owed to any person in relation to, or in connection with, the Information. The Information does not purport to contain all of the information that may be required to evaluate the Company and may be in preliminary or draft form. The Information is subject to updating, completion, revision, verification and amendment, and such information may change materially. Neither Cairn nor the Company nor their respective Affiliates are under any obligation to verify, update or keep current the Information. The Information may contain forward-looking statements, which relate, inter alia, to the Company’s proposed strategy, plans and objectives. Forward-looking statements are sometimes identified by the use of terminology such as “believes”, “expects”, “may”, “will”, “could”, “should” “shall”, “risk”, “intends”, “estimates”, “aims”, “plans”, “predicts”, “continues”, “assumes”, “positions” or “anticipates” or the negatives thereof, other variations thereon or comparable terminology. By their very nature, such forward-looking information requires the Company to make assumptions that may or may not materialise. Such forward-looking statements may be price sensitive and involve known and unknown risks, uncertainties and other important factors beyond the control of the Company that could cause any actual performance or achievements of the Company to be materially different from such forward-looking statements. Past performance of the Company cannot be relied upon as a guide to future performance. Accordingly, you should not rely on any forward-looking statements and neither the Company nor Cairn nor their respective Affiliates accept any obligation to disseminate any updates or revisions to such forward-looking statements or any other statements in the Information. No statement in the Information is intended as a profit forecast or a profit estimate and no statement in the Information should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. The Information contains certain financial information within the meaning of the MAR Directive and is subject to rounding and approximation. The Information may also contain management estimates. Such estimates have been made in good faith and represent the genuine belief of applicable members of management. Those management members believe that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete, and no representation or warranty (express or implied) is given that such estimates are so founded. The Company, Cairn and their Affiliates do not undertake any obligation to correct or complete any estimate whether as a result of becoming aware of information (new or otherwise), future events or otherwise. The Information may contain certain material information that is confidential, price-sensitive and which has not been publically disclosed. By your receipt of this Presentation you recognise and accept that some or all of the information in this Presentation may be “inside information” as defined in Article 7 of the Market Abuse Regulation (Regulation 596/2014) (“MAR”) and section 56 of the Criminal Justice Act 1993 (“CJA”). You recognise and accept that such information is being provided to you by the Company pursuant to Article 17(8) of MAR and Disclosure Guidance and Transparency Rule 2.5.7G(2) and you confirm, warrant and undertake that you will not: (i) deal in securities that are price-affected securities (as defined in the CJA) in relation to the inside information or encourage another person to deal in price-affected securities or disclose the information except as permitted by the CJA or before the inside information is made public; (ii) deal or attempt to deal in a financial instrument to which MAR applies on the basis of the inside information; (iii) disclose the inside information to another person other than in the proper course of the exercise of your employment, profession or duties; or (iv) engage in behaviour based on any inside information which would breach MAR. The Information is only directed at, persons who are: (a) outside of the United States; (b) in member states of the European Economic Area other than the United Kingdom and who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (as defined below); and (c) in the United Kingdom and are qualified investors and also (i) persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); (ii) high net worth entities falling within falling within Articles 49(2)(a) to (d) of the Order; or (iii) other persons to whom it can otherwise lawfully be published (each a “Relevant Person”). If you have received the Information and you are not a Relevant Person, you must return it (to the extent technologically feasible) to Stifel or the Company immediately. The Information should not be distributed, published, reproduced or otherwise made available in whole or in part by its recipients to any other person or in any other country, locality, state or other jurisdiction where such distribution, publication, availability or use may lead to a breach of any legal or regulatory requirement and, in particular the Slides may not be taken or transmitted or distributed, directly or indirectly, into the United States, or to persons with an address in Australia, the Republic of South Africa, Japan or Canada. It is a condition of you attending the Presentation or receiving the Information that you agree to be bound by the foregoing limitations and restrictions and, in particular, you will be taken to further represent, warranted and undertake that: (i) you have read and agree to comply with the contents of this disclaimer; (ii) you are a Relevant Person and you will observe the foregoing provisions, limitations and conditions; (iii) you will keep the Information confidential and take reasonable steps to preserve such confidentiality; and (iv) following the Presentation, you will not at any time have any discussion, correspondence or contact concerning the Information with any of the directors or employees of the Company or its subsidiaries nor with any of their suppliers or customers, or any governmental or regulatory body without the prior written consent of the Company.
Presenting Team

Lyn Rees  
Chief Executive Officer

- Joined July 2018
- 18 years with BBI Group, most recently as CEO for nine years
- Expertise in executing organic and acquisitive growth initiatives including product diversification and commercial globalization
- Completed and integrated seven acquisitions during his tenure at BBI Group

Barry Hextall  
Chief Financial Officer

- Joined June 2015
- Significant experience in medical device, instrumentation and diagnostic sectors including with Immunodiagnostic Systems plc, JRI Orthopaedics and Zeneca (formerly ICI)
- Chartered Management Accountant
Table of Contents

• Overview of Yourgene Health plc
• Financial Information
• Business Update

Appendix
• Additional information
About Yourgene Health PLC
Yourgene Health
Company Overview

- International molecular diagnostics group developing and commercialising genetic screening products and services
- Proprietary DNA analysis technology used to develop safer and improved non-invasive screening tests
- Acquired Yourgene Bioscience in March 2017, Elucigene Diagnostics in April 2019 and AGX-DPNI in March 2020
- Group has a suite of leading CE-IVD NGS & PCR products focused on reproductive health and precision medicine
- AIM listed (YGEN) on London Stock Exchange. Headquarters in Manchester, UK with facilities in Singapore, US and Taiwan

A leading NIPT test over 99% accurate\(^{(1)}\). A comprehensive menu in Reproductive Health and Molecular Genetics. Growing Oncology and Infectious Disease offering.

87% revenue growth year on year to £16.6m (2019: £8.9m)

First adjusted EBITDA of £1.3m, +£4.7m improvement from 2019

Sales in over 60 countries, now including US

Blue chip global partnerships
# Strategic priorities for growth

<table>
<thead>
<tr>
<th>Organic</th>
<th>Inorganic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product penetration</strong></td>
<td><strong>M&amp;A</strong></td>
</tr>
<tr>
<td><em>Sell More in Existing Channels</em></td>
<td><strong>Consolidator in the Market</strong></td>
</tr>
<tr>
<td>Drive worldwide sales of NIPT, Reproductive Health &amp; molecular genetics products and services by targeting further expansion through direct and key distribution channels</td>
<td>Delivering integration benefits of the Elucigene acquisition, creating a strong platform for future M&amp;A activity</td>
</tr>
<tr>
<td><strong>Geographic expansion</strong></td>
<td></td>
</tr>
<tr>
<td><em>Sell into New Territories</em></td>
<td></td>
</tr>
<tr>
<td>Expand directly and through distributors into new geographies, including those opened up by Illumina licence agreement</td>
<td></td>
</tr>
<tr>
<td><strong>Product expansion</strong></td>
<td></td>
</tr>
<tr>
<td><em>New Product Lines and Content</em></td>
<td></td>
</tr>
<tr>
<td>Leverage our technical and regulatory expertise and partnerships to extend our genetic testing offering</td>
<td></td>
</tr>
<tr>
<td>Support diagnostic majors and bioinformatics specialists with IVD product contract development partnerships</td>
<td></td>
</tr>
</tbody>
</table>
Yourgene Health Value Proposition

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services.

The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Expanding product portfolio of clinically relevant IVD products and services

Broad technology & platform capabilities to suit customer and market needs

International lab footprint, established routes to commercialisation
Product Portfolio

Clarity from complexity

NIPT

Reproductive Health

Molecular Genetics
* Oncology
* Research Services
* Infectious Diseases
* Core Technology

Growing Technology Portfolio

Growing Geographical Reach

Growing Product and Service Portfolio

© The Yourgene Health group of companies
Financial information:
Full Year Results to 31 March 2020
Revenue growth driven by global progress

Revenue progression

Revenues by segment £m

Commentary

- Revenues up 87% to £16.6m from £8.9m
- 36% organic growth
- Revenues enhanced by acquisitions of Elucigene Diagnostics (UK) in April 2019 and AGX-DPNI (Fra) in March 2020
- Elucigene delivered +12% like for like growth
- Strong growth against all regions
- Gross profits grew 122% to £10.2m from £4.6m
- Gross margin increased to 62%
2020 Financial Highlights

Income statement & bridge

Commentary

- First adjusted EBITDA as operational gearing reaches scale
- £4.7m improvement in adjusted EBITDA* to £1.3m from (2019: loss of £3.4m)
- Operating loss reduced to £3.2m from £4.8m, with half of 2020 figure being due to non-cash share-based payments charge
2020 Financial Highlights

Statements of Financial Position & Cashflows

Commentary

- Cash used by operations halved to £2.1m (2019: £4.0m); positive before growth working capital
- Cash and cash equivalents at 31 March 2020 of £2.8m (31 March 2019: £1.3m)
- Post period end receipts of £0.8m for warrants / options exercise and £0.5m for R&D tax credit
- Net cash (cash less borrowings) improved to £2.4m (31 March 2019: net cash of £1.0m)
Business Update
Yourgene inorganic strategic growth plan
M&A track record

• Elucigene Diagnostics (UK) acquired April 2019; 2.5x revenue / 9x EBITDA
  • 20% synergy savings
  • 12% like for like revenue growth in year 1
  • Global expansion, increased from 30 to over 60 countries
  • Expanded product portfolio with PCR-based reproductive health range

• AGX-DPNI (France) acquired March 2020; 4x incremental EBITDA
  • Immediate EBITDA uplift of c. £0.5m pa from internalising distributor margin in year 1
  • Market penetration - closer to NIPT customers ahead of IONA® Nx NIPT roll-out
  • Access to new French speaking markets
  • On track to reach first ratchet target based on accelerated growth
Product & Service Expansion
Growing our portfolio

• Expanded our Molecular Genetics portfolio to include the following:
  • Infectious Disease range:
    • Launched Clarigene™ SARS CoV-2 Test RUO
    • Clarigene™ SARS CoV-2 Test CE-IVD (due summer 2020)
  • Core Technology enablers – launched Yourgene Flex™ Analysis Software
  • Oncology – launched our first precision medicine DPYD test for chemotoxicity
  • Research Services – capabilities now in Manchester as well as Taipei including:
    • Whole genome sequencing, Whole exome sequencing
    • Library construction, DNA / RNA extraction

• IONA® Nx NIPT Workflow – receives CE mark and commercially available

• Active pipeline of new products and services in our roadmap planned
  • New complementary oncology products to support DPYD
  • New reproductive and NIPT products planned
IONA® Nx NIPT Workflow

CE-IVD launch and commercial roll-out

- CE-IVD mark received for the IONA® Nx NIPT Workflow on 15th June 2020. It runs on the Illumina NextSeq 550Dx Next Generation Sequencing platform.
- We are planning to install the test to run as part of our own laboratory service run from our facilities in Manchester.
- Planning and scheduling is underway with existing IONA® customers across Europe to transition to the IONA Nx.
- Market development planning for the introduction of IONA® Nx in new territories.
- Schedule of regulatory submissions to allow launch into new regions over the coming months.
Geographical Reach

• Excellent progress in expanding our commercial footprint into new territories including:
  
  • Yourgene Health Inc established in USA with our first US sales role and first US revenue
  
  • Present in over 60 countries compared with 30 last year
  
  • Expanded our European sales team with key appointments to support the IONA® Nx NIPT roll-out
Infectious Disease Portfolio
Responding to COVID-19

Three fold commercial response, utilising the companies expertise across of service testing, contract manufacture and product development:

• COVID-19 testing service laboratory in Manchester processing non-NHS samples from corporate partners and private healthcare professionals incl. Caxton FX

• Approved supplier contract manufacturing project for components of a partners SARS CoV-2 kit

• Launched Clarigene portfolio of infectious disease products: Clarigene:
  • SARS CoV-2 RUO (launched June 2020)
  • Clarigene SARS CoV-2 CE-IVD (due summer 2020)

• There is unprecedented global demand for COVID-19 testing but the market is dynamic and unpredictable as a result.
Outlook

• Roll-out of the new IONA® Nx NIPT Workflow to existing and new regions - it combines this gold standard for reliability and accuracy with a market leading sequencer and we believe this will be a strong driver of growth in the future.

• Launch of the CE-marked version of the Clarigene™ SARS CoV-2 Test - will have two viral targets and assay controls, making it more desirable from the reimbursement perspective across several European regions

• We understand that the COVID-19 testing market is dynamic and, to a certain extent, unpredictable as a result

• Market forecasts for 2021 and beyond see our growth trajectory continuing and heralds a move towards full profitability in the near term

• We remain confident that we can deliver against these forecasts and that both IONA Nx and our Clarigene products will be major contributors to this growth
www.yourgene-health.com

Yourgene Health Plc
Citylabs 1.0
Nelson Street
Manchester
M13 9NQ
United Kingdom

Telephone: +44 (0)161 669 8122
Email: investors@yourgene-health.com

Lyn Rees – CEO
Email: lyn.rees@yourgene-health.com
Tel: +44 (0)161 669 8122

Barry Hextall – CFO
Email: barry.hextall@yourgene-health.com
Tel: +44 (0)161 669 8122